Citadel Advisors
KROS icon

Citadel Advisors’s Keros Therapeutics KROS Stock Holding History

Citadel Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.43M Sell
129,900
-73,500
-36% -$1.13M ﹤0.01% 6819
2025
Q4 		$4.14M Buy
203,400
+156,600
+335% +$2.75M ﹤0.01% 4585
2025
Q3 		$740K Sell
46,800
-26,500
-36% -$391K ﹤0.01% 8213
2025
Q2 		$979K Sell
73,300
-65,400
-47% -$883K ﹤0.01% 7142
2025
Q1 		$1.41M Buy
138,700
+75,200
+118% +$873K ﹤0.01% 6203
2024
Q4 		$1.01M Buy
63,500
+58,200
+1,098% +$3.02M ﹤0.01% 7001
2024
Q3 		$308K Buy
5,300
+3,500
+194% +$173K ﹤0.01% 9288
2024
Q2 		$82.3K Sell
1,800
-3,200
-64% -$172K ﹤0.01% 11173
2024
Q1 		$331K Buy
5,000
+2,900
+138% +$172K ﹤0.01% 9247
2023
Q4 		$83.5K Buy
2,100
+2,000
+2,000% +$62.7K ﹤0.01% 11161
2023
Q3 		$3.19K Sell
100
-400
-80% -$14.9K ﹤0.01% 13621
2023
Q2 		$20.1K Buy
500
+400
+400% +$17.5K ﹤0.01% 12721
2023
Q1 		$4.27K Buy
+100
New +$5.05K ﹤0.01% 13970

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors's KROS Position: Q1 2026 in Review

Citadel Advisors reduced its Keros Therapeutics (KROS) stake by 14% in Q1 2026, selling an estimated $1.02M and leaving 406,666 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #4521.

Citadel Advisors first reported a position in KROS in Q2 2020 and has held it in 23 quarters since. The position peaked at $40.9M in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Citadel Advisors held 406,666 shares of Keros Therapeutics worth $4.49M as of Q1 2026.
  • Citadel Advisors sold 65,854 Keros Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Keros Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4521 holding.
  • Citadel Advisors first reported a position in Keros Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Keros Therapeutics position peaked at $40.9M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.